When hyperglycemia and hyperinsulinemia are alleviated by SGLT2-i administration, these changes are alleviated, which eventually leads to the improvement of obesity and fatty liver. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.